Cenobamate in pediatric drug-resistant epilepsy: real-world evidence from a two-center retrospective study

A two-center retrospective study evaluated cenobamate as adjunctive therapy in 65 children (median age 11.5 years) with focal drug-resistant epilepsy, finding that 75% improved with treatment and 44.6% achieved >50% seizure reduction. Adverse events occurred in over half of participants, though the abstract was truncated before complete safety details.